Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL)

Authors :: Juan José Reina
Adelaida La Casta Munoa
Guillermo Alfonso Quintero Aldana
Silvia Gil
Encarnación González Flores
Rafael López
Mercedes Salgado Fernández
Pilar Alfonso
Eduardo Díaz-Rubio
A. Gomez
Jose María Vieitez
Ma. José Flor Oncala
Beatriz García-Paredes
Antonieta Salud Salvia
Begoña Graña Suárez
Maria Jose Safont
Guillot Mónica
Mercedes Rodríguez Garrote
Eva Martínez de Castro
Enrique Aranda
Source :: Journal of Clinical Oncology. 36:3536-3536
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 3536Background: FOLFOXIRI plus bevacizumab has demonstrated a survival benefit compared with FOLFIRI plus bevacizumab (TRIBE Lancet Oncol 2015) in first-line mCRC. This schedule is not routinely re...

Full Text Access

Tools